Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB

Cellular Physiology and Biochemistry

Volumn 30, Issue 3, 2012, Pages 499-511

  Lee, Dong Kun ^a   Park, Eun Ju ^a   Kim, Eun Kyoung ^a   Jin, Junyup ^a   Kim, Jong Soo ^a   Shin, Ik Jae ^b   Kim, Bo Yeon ^b   Lee, Hookeun ^c   Kim, Dong Eog ^b  

^a Songdo Global University Campus   (South Korea)

^b Dongguk University Ilsan Hospital   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

CREB; ERK; LPS; Macrophage; MMP 9; Statin

Indexed keywords

ATORVASTATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GELATINASE B; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PRAVASTATIN; SIMVASTATIN; TRICHOSTATIN A;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EXTRACELLULAR CALCIUM; GENE EXPRESSION; MACROPHAGE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ZYMOGRAPHY;

MURINAE;

EID: 84863871129     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000341433     Document Type: Article

References (45)

1. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH: Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006;12:441-445.
2. Lim CS, Shalhoub J, Gohel MS, Shepherd AC, Davies AH: Matrix metalloproteinases in vascular disease-a potential therapeutic target? Curr Vase Pharmacol 2010;8:75-85.
3. Kim DE, Kim JY, Schellingerhout D, Kim E], Kim HK, Lee S, Kim K, Kwon IC, Shon SM, Jeong SW, lm SH, Lee DK, Lee MM, Kim GE: Protease imaging of human atheromata captures molecular information of atherosclerosis, complementing anatomic imaging. Arterioscler Thromb Vase Biol 2010;30:449-456.
4. Shon SM, Park JH, Nahrendorf M, Schellingerhout D, Kim JY, Kang BT, Jeong SW, Kim EJ, Ryu JH, Kim K, Kwon IC, Lee DK, Lee MM, Kim DE: Exercise attenuates matrix metalloproteinase activity in preexisting atherosclerotic plaque. Atherosclerosis 2011;216:67-73.
5. Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, DArmiento J: Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 2008;294:L1149-1157.
6. Del Zoppo GJ, Frankowski H, Gu YH, Osada T, Kanazawa M, Milner R, Wang X, Hosomi N, Mabuchi T, Koziol JA: Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation. J Cereb Blood Flow Metab 2012
7. Rouis M: Matrix metalloproteinases: A potential therapeutic target in atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:541-548.
8. Mackman N, Brand K, Edgington TS: Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in thp-1 monocytic cells requires both activator protein 1 and nuclear factor kappa b binding sites. J Exp Med 1991;174:1517-1526.
9. Lin CC, Tseng HW, Hsieh HL, Lee CW, Wu CY, Cheng CY, Yang CM: Tumor necrosis factor-alpha induces mmp-9 expression via p42/p44 mapk, jnk, and nuclear factor-kappab in a549 cells. Toxicol Appl Pharmacol 2008;229:386-398.
10. Masure S, Nys G, Fiten P, Van Damme J, Opdenakker G: Mouse gelatinase b. Cdna cloning, regulation of expression and glycosylation in wehi-3 macrophages and gene organisation. Eur J Biochem 1993;218:129-141.
11. Mario M, Giardino-Torchia ML, Sankar U, Ribar TJ, Galgani M, Vitiello L, Masci AM, Bertani FR, Ciaglia E, Astone D, Maulucci G, Cavallo A, Vitale M, Cimini V, Pastore L, Means AR, Rossi G, Racioppi L: Calmodulin-dependent kinase iv links toll-like receptor 4 signaling with survival pathway of activated dendritic cells. Blood 2008;111:723-731.
12. Zanoni I, Ostuni R, Capuano G, Collini M, Caccia M, Ronchi AE, Rocchetti M, Mingozzi F, Foti M, Chirico G, Costa B, Zaza A, Ricciardi-Castagnoli P, Granucci F: Cdl4 regulates the dendritic cell life cycle after lps exposure through nfat activation. Nature 2009;460:264-268.
13. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999;282:2340-2346.
14. Bu DX, Griffin G, Lichtman AH: Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 2011;22:165-170.
15. Greenwood J, Steinman L, Zamvil SS: Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-370.
16. Biasucci LM, Biasillo G, Stefanelli A: Inflammatory markers, cholesterol and statins: Pathophysiological role and clinical importance. Clin Chem Lab Med 2010;48:1685-1691.
17. Gargiulo S, Sottero B, Gamba P, Chiarpotto E, Poli G, Leonarduzzi G: Plaque oxysterols induce unbalanced up-regulation of matrix metalloproteinase-9 in macrophagic cells through redox-sensitive signaling pathways: Implications regarding the vulnerability of atherosclerotic lesions. Free Radie Biol Med 2011;51:844-855.
18. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003;289:1681-1690.
19. Egan A, Colman E: Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 2011;365:285-287.
20. Koh KK, Sakuma I, Quon MJ: Differential metabolic effects of distinct statins. Atherosclerosis 2011;215:1-8.
21. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
22. Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, Heine H: Tlr4-mediated inflammatory activation of human coronary artery endothelial cells by lps. Cardiovasc Res 2002;56:126-134.
23. Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C, Distante A, De Caterina R: Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: Anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res 2010;86:311-320.
24. Monick MM, Powers LS, Butler NS, Hunninghake GW: Inhibition of rho family gtpases results in increased tnf-alpha production after lipopolysaccharide exposure. Immunol 2003;171:2625-2630.
25. Konat GW, Krasowska-Zoladek A, Kraszpulski M: Statins enhance toll-like receptor 4-mediated cytokine gene expression in astrocytes: Implication of rho proteins in negative feedback regulation. Neurosci Res 2008;86:603-609.
26. Lee E], Kim HS: Inhibitory mechanism of mmp-9 gene expression by ethyl pyruvate in lipopolysaccharide-stimulated bv2 microglial cells. Neurosci Lett 2011;493:38-43.
27. 2 *-and protein kinase c-dependent signaling pathway for nuclear factor-kappab activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-alpha production in lipopolysaccharide-stimulated rat peritoneal macrophages. Biol Chem 2006;281:31337-31347.
28. Park JK, Park SH, So K, Bae IH, Yoo YD, Um HD: Icam-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing mmp-2 and mmp-9 via akt and creb. Int Oncol 2010;36:181-192.
29. Caivano M, Cohen P: Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and ill beta in raw264 macrophages. Immunol 2000;164:3018-3025.
30. AdcockIM: Hdac inhibitors as anti-inflammatory agents. Br] Pharmacol 2007;150:829-831.
31. Yu Z, Zhang W, Kone BC: Histone deacetylases augment cytokine induction of the inos gene. Am Soc Nephrol 2002;13:2009-2017.
32. Cohen LH, van Vliet A, Roodenburg L, Jansen LM, Griffioen M: Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line hep g2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase and squalene synthase. Biochem Pharmacol 1993;45:2203-2208.
33. Gerber R, Ryan JD, Clark DS: Cell-based screen of hmg-coa reductase inhibitors and expression regulators using lc-ms. Anal Biochem 2004;329:28-34.
34. Akool el S, Kleinert H, Hamada FM, Abdelwahab MH, Forstermann U, Pfeilschifter J, Eberhardt W: Nitric oxide increases the decay of matrix metalloproteinase 9 mrna by inhibiting the expression of mrna-stabilizing factor hur. Mol Cell Biol 2003;23:4901-4916.
35. Hosokawa Y, Hosokawa I, Ozaki K, Nakanishi T, Nakae H, Matsuo T: Catechins inhibit cxcllO production from oncostatin m-stimulated human gingival fibroblasts. Nutr Biochem 2009;21:659-664.
36. Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vene R, Dell'Eva R, Jochum M, Albini A, Pfeffer U: The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 2007;19:137-152.
37. Coultrap S, Vest RS, Ashpole NM, Hudmon A, Bayer KU: Camkii in cerebral ischemia. Acta Pharmacol Sin 2011;32:861-872.
38. Domercq M, Perez-Samartin A, Aparicio D, Alberdi E, Pampliega 0, Matute C: P2x7 receptors mediate ischemic damage to oligodendrocytes. Glia 2010;58:730-740.
39. Davidson JO, Green CR, Nicholson LF, O'Carroll S], Fraser M, Bennet L, Gunn AJ: Connexin hemichannel blockade improves outcomes in a model of fetal ischemia. Ann Neurol 2012;71:121-132.
40. 2 *pathway. Circ Res 2006;99:590-597.
41. Mason RP, Walter MF, Day CA, Jacob RF: Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005;96:11F-23E
42. Ma Z, Shah RC, Chang MJ, Benveniste EN: Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription. Mol Cell Biol 2004;24:5496-5509.
43. Dokmanovic M, Clarke C, Marks PA: Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 2007;5:981-989.
44. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA, Mascagni P: The histone deacetylase inhibitor itf2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005;11:1-15.
45. Rosell A, Lo EH: Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008;8:82-89.